William Blair analyst Ryan Daniels has maintained their bullish stance on PHR stock, giving a Buy rating today.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 55% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Ryan Daniels has given his Buy rating due to a combination of factors, including Phreesia’s strong financial performance and strategic acquisitions. The company reported second-quarter fiscal 2026 results that exceeded market expectations in both revenue and adjusted EBITDA. With revenue reaching $117.3 million, Phreesia demonstrated a 15% year-over-year growth, driven by significant increases in network solutions and payments processing.
Additionally, Phreesia’s management has raised its adjusted EBITDA guidance, reflecting confidence in the company’s operational leverage. The acquisition of AccessOne is another strategic move, expected to enhance Phreesia’s market position by expanding its addressable market by approximately $6 billion. This acquisition is anticipated to contribute significantly to the company’s revenue and EBITDA, further supporting the Buy rating.
Daniels covers the Healthcare sector, focusing on stocks such as Addus Homecare, Healthcare Services, and Idexx Laboratories. According to TipRanks, Daniels has an average return of 10.2% and a 53.95% success rate on recommended stocks.
In another report released today, TR | OpenAI – 4o also reiterated a Buy rating on the stock with a $34.00 price target.